Registrieren

Registierung erfolgt in Kürze...
Fleebs-Logo
Details werden geladen...

Agendia, Inc.: Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage B...

Additional research highlights integration of BluePrint molecular subtyping and ImPrint immune profiling to optimize prediction of neoadjuvant treatment response in HER2-positive early-stage breast

Ähnliche Seiten

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/roche-to-present-new-data-at-asco-2026-reinforcing-giredestrants-potential-to-transform-the-treatment-paradigm-in-early-breast-cancer/2346752

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer | The Manila Times

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/roche-to-present-new-data-at-asco-2026-reinforcing-giredestrants-potential-to-transform-the-treatment-paradigm-in-early-breast-cancer/2346752
https://www.finanznachrichten.de/nachrichten-2026-05/68530387-f-hoffmann-la-roche-ltd-roche-to-present-new-data-at-asco-2026-reinforcing-giredestrant-s-potential-to-transform-the-treatment-paradigm-in-early-br-399.htm

F. Hoffmann-La Roche Ltd: Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

https://www.finanznachrichten.de/nachrichten-2026-05/68530387-f-hoffmann-la-roche-ltd-roche-to-present-new-data-at-asco-2026-reinforcing-giredestrant-s-potential-to-transform-the-treatment-paradigm-in-early-br-399.htm
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349713

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349713
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/cullinan-therapeutics-to-present-initial-clinical-data-for-cln-978-in-treatment-refractory-rheumatoid-arthritis-and-systemic-lupus-erythematosus-at-eular-2026-congress/2346652

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress | The Manila Times

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/cullinan-therapeutics-to-present-initial-clinical-data-for-cln-978-in-treatment-refractory-rheumatoid-arthritis-and-systemic-lupus-erythematosus-at-eular-2026-congress/2346652
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/perspective-therapeutics-to-present-data-from-all-clinical-programs-at-the-2026-asco-annual-meeting-including-findings-from-212pbvmt01-in-melanoma/2349731

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/perspective-therapeutics-to-present-data-from-all-clinical-programs-at-the-2026-asco-annual-meeting-including-findings-from-212pbvmt01-in-melanoma/2349731
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/zentalis-pharmaceuticals-to-present-phase-1b-muir-trial-data-showing-encouraging-clinical-activity-and-manageable-safety-profile-of-azenosertib-plus-paclitaxel-in-platinum-resistant-ovarian-cancer-at-asco-2026/2349725

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at...

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/zentalis-pharmaceuticals-to-present-phase-1b-muir-trial-data-showing-encouraging-clinical-activity-and-manageable-safety-profile-of-azenosertib-plus-paclitaxel-in-platinum-resistant-ovarian-cancer-at-asco-2026/2349725